We are doing this study to learn more about whether a drug called semaglutide (Rybelsus®) affects behaviors associated with Alcohol Use Disorder (AUD). Semaglutide is approved by the Food and Drug Administration (FDA) for the treatment of Type 2 diabetes but is not approved for AUD treatment.
You will be randomly assigned to one of two groups. You will have a 50% (1 in 2) chance of receiving semaglutide and a 50% chance of receiving placebo. This is a double-blind study, which means neither you nor the study investigator will make the choice to which group you are assigned, and neither will know what group you are in. There are 8 study visits over about 11 weeks, including weekly study visits for 7 weeks, plus a follow-up phone call about two weeks after the last study visit. Compensation is provided for participation.
- Age 21 or older - Drink regularly and meet criteria for Alcohol Use Disorder (AUD) - Interested in reducing or stopping your alcohol use Not everyone will qualify to be in the study. Other inclusion and exclusion criteria will be evaluated by the study team.
Principal Investigator